CN113796546A - 改善肠道屏障功能母乳低聚糖组合物及其应用 - Google Patents
改善肠道屏障功能母乳低聚糖组合物及其应用 Download PDFInfo
- Publication number
- CN113796546A CN113796546A CN202111067369.0A CN202111067369A CN113796546A CN 113796546 A CN113796546 A CN 113796546A CN 202111067369 A CN202111067369 A CN 202111067369A CN 113796546 A CN113796546 A CN 113796546A
- Authority
- CN
- China
- Prior art keywords
- breast milk
- milk oligosaccharide
- oligosaccharide composition
- gos
- infant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 26
- 235000020256 human milk Nutrition 0.000 title claims abstract description 25
- 210000004251 human milk Anatomy 0.000 title claims abstract description 25
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 25
- 230000007358 intestinal barrier function Effects 0.000 title description 16
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 27
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 21
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 11
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 9
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 9
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 9
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000001072 colon Anatomy 0.000 claims abstract description 6
- 235000013350 formula milk Nutrition 0.000 claims abstract description 5
- 230000004888 barrier function Effects 0.000 claims abstract description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 12
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 12
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 8
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 8
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 22
- 235000008452 baby food Nutrition 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 description 25
- 230000004151 fermentation Effects 0.000 description 24
- 235000013406 prebiotics Nutrition 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 210000003608 fece Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 5
- 235000021391 short chain fatty acids Nutrition 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 229940107187 fructooligosaccharide Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 2
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000600 Claudin-1 Proteins 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- NHWZQIYTQZEOSJ-UHFFFAOYSA-N carbonic acid;phosphoric acid Chemical compound OC(O)=O.OP(O)(O)=O NHWZQIYTQZEOSJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 102000004162 Claudin-1 Human genes 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- -1 fucosyl oligosaccharide Chemical class 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
Abstract
本发明涉及一种母乳低聚糖组合物及其应用,其中包括2’‑FL(2’‑岩藻糖基乳糖)和GOS(低聚半乳糖),其中2’‑FL与GOS的重量比例为1:1.5‑2.5。本发明发现,以特定质量比的2’‑FL(2’‑岩藻糖基乳糖)和GOS(低聚半乳糖)的组合,可以显著协同促进婴儿结肠产短链脂肪酸、减少气体产生并维持双歧杆菌优势地位,改善肠道屏障功能。本发明的母乳低聚糖组合物能显著改善肠道微环境健康,可用于添加在婴幼儿食品(包括婴幼儿配方粉、辅食、营养补充剂),以及3岁以上儿童、青少年和成人的营养补充剂或食品中,具有广阔的应用前景。
Description
技术领域
本发明属于医药技术领域,具体涉及一种改善肠道屏障功能母乳低聚糖组合物及其应用。
背景技术
肠道菌群结构和组成与婴儿的健康息息相关,稳定的肠道菌群组成有助于有效的肠道屏障的建立以及平衡的粘膜免疫系统的组成。婴儿的肠道菌群结构对于成人来说相对简单,以双歧杆菌属、拟杆菌属、梭菌属、乳杆菌属、链球菌属、粪杆菌属等为主。影响其肠道菌群的因素也相对可控,有利于研究单一因素对其肠道菌群的影响。对于婴儿来说,其肠道菌群容易受各种遗传因素和环境因素的影响。而且饮食的改变或者抗生素的使用等都可能会导致婴儿获得免疫相关的疾病,如过敏、肠绞痛或者肠炎。因此,健康的肠道菌群环境有助于促进婴儿的健康发展。
母乳低聚糖(human milk oligosaccharides,HMOs)是母乳中重要的生物活性成份,也是影响婴儿肠道菌群组成的重要因素之一,具有结构多样性,目前已检测出超过200种结构。由于它在婴儿的肠道当中能够发挥益生元效应并且引导婴儿肠道菌群稳定以及建立更健康的肠屏障功能和促进粘膜免疫系统的发育,近几年来备受科学家们关注。HMOs在上消化道当中是不被消化的,所以HMOs会直接到达婴儿的大肠并且刺激婴儿肠道中的有益菌,比如双歧杆菌或者乳酸菌的生长,并产生对婴儿健康有益的短链脂肪酸和乳酸。除了刺激肠道中有益菌的生长外,HMOs还可以直接影响到婴儿粘膜免疫系统和肠屏障功能的建立。
近年来国内外众多研究已经阐明了HMOs对婴儿肠道的有益影响,但是由于HMOs结构众多,性质复杂,不同结构的HMOs对肠道的影响是不同的,目前关于不同结构的HMOS对婴儿肠道的发酵特性以及肠屏障功能的评价并不全面,缺乏HMOs对不同类型的婴儿肠道菌群作用的深入研究。
中国专利申请CN112514997A公开了改善肠道微环境健康的母乳低聚糖及其应用。具体地,本发明提供了母乳低聚糖特别是岩藻糖基类低聚糖2’-FL(2’-岩藻糖基乳糖)或3-FL(3-岩藻糖基乳糖)在制备用于改善肠道微环境健康的食品中的应用,其中,所述改善肠道微环境健康包括:在肠道系统中作为益生元被肠道菌群利用并产气,降低pH以维持肠道微环境健康,和/或减少支链脂肪酸如异丁酸和/或异戊酸。本发明的母乳低聚糖用于添加在婴幼儿食品(包括婴幼儿配方粉、辅食、营养补充剂),以及3岁以上儿童、青少年和成人的营养补充剂或食品中,具有广阔的应用前景。该专利申请关注的是单一母乳低聚糖的作用。
中国专利申请CN112075637A公开了一种减少肠道气体产生的组合物途,所述组合用于制备一营养组合物或制剂,所述营养组合物用于:(a)减少婴幼儿肠道气体的产生;和/或(b)抑制婴幼儿肠道产气梭菌的过度生长;其中,所述营养组合物中包括:(i)一种母乳低聚糖(HMO);和(ii)一种益生菌微生物,所述益生菌微生物包括双歧杆菌。本发明的组合或营养组合物可以显著降低婴幼儿肠道产气、可较优的改善腹胀以及腹绞痛婴儿的肠道菌群。但该专利申请重点关注的是肠道产气,而没有涉及肠道短链脂肪酸和支链脂肪酸的平衡以及维持双歧杆菌优势地位。
发明内容
基于上述背景技术,本发明所要解决的技术问题在于提供能促进婴儿结肠产短链脂肪酸、减少气体产生并维持双歧杆菌优势地位,改善肠道屏障功能的益生元母乳低聚糖组合物。为了实现本发明的发明目的,拟采用如下技术方案:
本发明一方面涉及一种母乳低聚糖组合物,其中包括2’-FL(2’-岩藻糖基乳糖)和GOS(低聚半乳糖),其中2’-FL与GOS的重量比例为1:1-3;优选为1:1.8-2.2;最优选为1:2。
在本发明的另一个优选实施方式中,所述的母乳低聚糖组合物还包括瑞士乳杆菌(Lactobacillus helveticus R52)、婴儿双歧杆菌(Bifidobacterium infantis R33)和/或两歧双歧杆菌(Bifidobacterium bifidum R71)。
在本发明的另一个优选实施方式中,所述的母乳低聚糖组合物还包括婴儿双歧杆菌(Bifidobacterium infantis R33);优选的,所述婴儿双歧杆菌(Bifidobacteriuminfantis R33)与2’-FL(2’-岩藻糖基乳糖)的重量比为0.4-0.6:1,其中婴儿双歧杆菌的浓度为106~1011CFU/g。
本发明另一方面涉及一种食品,其包括上述母乳低聚糖组合物,所述低聚糖组合物在食品中的终浓度为100mg/100g~104mg/100g。
在本发明的一个优选实施方式中,所述食品为营养补充剂、婴幼儿配方粉、辅食。
本发明另一方面还涉及上述母乳低聚糖组合物在制备改善微环境健康的食品中的应用。
在本发明的一个优选实施方式中,所述改善微环境健康包括能促进婴儿结肠产短链脂肪酸、减少气体产生并维持双歧杆菌优势地位,改善肠道屏障功能。
有益效果
本发明发现,以特定质量比的2’-FL(2’-岩藻糖基乳糖)和GOS(低聚半乳糖)的组合,可以显著协同促进婴儿结肠产短链脂肪酸、减少气体产生并维持双歧杆菌优势地位,改善肠道屏障功能。本发明的母乳低聚糖组合物能显著改善肠道微环境健康,可用于添加在婴幼儿食品(包括婴幼儿配方粉、辅食、营养补充剂),以及3岁以上儿童、青少年和成人的营养补充剂或食品中,具有广阔的应用前景。
附图说明
图1是示出益生元在发酵过程的产气动态的图;
图2是示出发酵24小时短链脂肪酸产量的图;
图3是示出发酵24h时样本中双歧杆菌属的相对丰度的图;
图4是示出发酵上清液对肠道屏障的作用的图。
图5是示出发酵上清液对肠道屏障的作用的图。
图6是示出发酵上清液对肠道屏障的作用的图。
具体实施方式
为了进一步理解本发明,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
如无特殊说明,本发明实施例中所涉及的试剂均为市售产品,均可以通过商业渠道购买获得。
实施例1:
2.1研究方法
研究对象:招募10名月龄为3-7月、无抗生素摄入的健康顺产母乳喂养婴儿并收集其粪便,粪便中优势菌群为双歧杆菌(相对丰度>50%)。
益生元:A:2’-FL(2’-岩藻糖基乳糖),B:GOS(低聚半乳糖),C:2’-FL+GOS(1:2),D:2’-FL+GOS(1:4),E:2’-FL+FOS(低聚果糖)(1:2)。
益生元与益生菌的组合:F:2’-FL+GOS+瑞士乳杆菌(Lactobacillus helveticusR52)(1:2:0.5),G:2’-FL+GOS+婴儿双歧杆菌(Bifidobacterium infantis R33)(1:2:0.5)
说明:上述比例指重量比
实验方法:1)体外大肠发酵:在厌氧环境下,分别将每份婴儿粪便与碳酸磷酸盐缓冲液按1:4(w/v)的比例混合并通过4层滤布过滤,制成粪便匀浆。将粪便浆液(1mL)、碳酸磷酸盐缓冲液(3mL)、50mg益生元或益生元与益生菌的组合(干基)分别加入厌氧瓶中并密封,于37℃恒温酵解4h、8h、12h和24h后取出,用于后续产气、产酸及菌群分析。2)代谢物含量测定:产气——使用标有刻度的注射器收集发酵气体进行气体产量测量;产酸——用气相色谱法测量发酵液中短链脂肪酸含量;菌群组成——通过16S rRNA序列分析法分析发酵前后的粪便菌群组成。
2.2结果分析
2.2.1发酵产气速率
益生元在发酵过程的产气动态如图1所示,A-G在发酵0-24h不断释放气体,不同组别的益生元在各发酵时间段的产气速率不同,其中C、F和G组合能够有效的降低产气速率,由此说明2’-FL+GOS以特定的比例进行组合有助于降低产气速率,具有明显的气体缓释作用,有助于减少婴儿肠胀气等不适症状。
2.2.2短链脂肪酸产量
益生元在发酵24h时的短链脂肪酸产量如图2所示,A-G组发酵过程中产生的SCFAs主要为乙酸以及少量丙酸和丁酸,其中C、F和G组合能够更有效促进肠道系统中对人体有益的乙酸、丙酸等短链脂肪酸的产生,由此说明2’-FL+GOS以特定的比例进行组合有助于短链脂肪酸的产生,特别是G组肠道有益代谢物短链脂肪酸的产生更加显著。
2.2.3益生元的肠道菌群调节作用
益生元对肠道菌群调节作用如图3所示,发酵前,10个婴儿个体粪便菌群以双歧杆菌为优势菌群,双歧杆菌属相对丰度>50%;A-G组益生元组合发酵24h后,可能由于发酵环境的影响,E组双歧杆菌丰度上升不显著,A-D,F-G组双歧杆菌都有显著的提升。但C、F和G组双歧杆菌作为各处理组中的优势菌属,上升最显著。由此说明C、F和G组对于显著升高双歧杆菌丰度,维持双歧杆菌优势地位具有改善作用,但三组之间没有实质性差异。
实施例2:
3.1研究方法
研究对象:招募10名月龄为3-7月、无抗生素摄入的健康顺产母乳喂养婴儿并收集其粪便,粪便中优势菌群为双歧杆菌(相对丰度>50%)。
益生元:A:2’-FL(2’-岩藻糖基乳糖),B:GOS(低聚半乳糖),C:2’-FL+GOS(1:2),D:2’-FL+GOS(1:4),E:2’-FL+FOS(低聚果糖)(1:2)。
益生元与益生菌的组合:F:2’-FL+GOS+瑞士乳杆菌(Lactobacillus helveticusR52)(1:2:0.5),G:2’-FL+GOS+婴儿双歧杆菌(Bifidobacterium infantis R33)(1:2:0.5)
说明:上述比例指重量比
实验方法:1)体外结肠发酵:根据实施例2进行体外结肠发酵获得发酵上清液即发酵代谢物。2)肠上皮细胞免疫功能测定:购买自美国典型菌种保藏中心(ATCC)的人Caco-2细胞。在37℃、5%CO2环境中,用含有10%FBS,1%双抗的1640培养基培养Caco-2细胞。将Caco-2细胞以6×105/cm2接种于1.33cm2的Transwell聚碳酸酯半透膜(0.4μm)上并在有10%FBS,1%双抗的1640培养基中生长21天。在实验当天,将用体外发酵收集的发酵代谢产物与1μg/mL的LPS共干预Caco-2细胞。具体来说,即用上述A-G 7种组合的发酵代谢物以稀释8倍的浓度与1μg/mL的LPS添加到Transwell的顶腔处。将仅有0.1μg/mL的LPS的组作为阴性对照组。在干预24h后,使用电阻仪测量经上皮电阻,同时将细胞裂解提取RNA,转录成cDNA后用RT-qPCR检测紧密连接蛋白(Occudin,ZO-2和Claudin-1)表达量。
3.2结果分析
3.2.1肠屏障功能
益生元对肠屏障功能的作用如图4、图5和图6所示,A-G组益生元组合干预Caco-2细胞24h后,均表现出不同程度的保护肠屏障功能的功效,其中C、F和G组合能够更有效提高TEER值,改善肠道屏障功能。A-G组合紧密连接蛋白的表达量均有增加。和其他组相比,C、F和G组合能够更显著提高ZO-2和Claudin-1紧密连接蛋白基因的表达量,改善肠道屏障功能。
以上描述了本发明优选实施方式,然其并非用以限定本发明。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。
Claims (7)
1.一种母乳低聚糖组合物,其中包括2’-FL(2’-岩藻糖基乳糖)和GOS(低聚半乳糖),其中2’-FL与GOS的重量比例为1:1-3;优选为1:1.8-2.2;最优选为1:2。
2.根据权利要求1所述的组合物,所述的母乳低聚糖组合物还包括瑞士乳杆菌(Lactobacillus helveticus R52)、婴儿双歧杆菌(Bifidobacterium infantis R33)和/或两歧双歧杆菌(Bifidobacterium bifidum R71)。
3.根据权利要求1所述的组合物,所述的母乳低聚糖组合物还包括婴儿双歧杆菌(Bifidobacterium infantis R33)。
4.一种食品,其包括权利要求1-3任意一项所述的母乳低聚糖组合物,所述低聚糖组合物在食品中的终浓度为100mg/100g~104mg/100g。
5.根据权利要求4所述的食品,所述食品为营养补充剂、婴幼儿配方粉、辅食。
6.权利要求1-3任意一项所述母乳低聚糖组合物在制备改善微环境健康的食品中的应用。
7.根据权利要求6所述的应用,所述改善微环境健康包括能促进婴儿结肠产短链脂肪酸、减少气体产生并维持双歧杆菌优势地位,改善肠道屏障功能。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111067369.0A CN113796546A (zh) | 2021-09-13 | 2021-09-13 | 改善肠道屏障功能母乳低聚糖组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111067369.0A CN113796546A (zh) | 2021-09-13 | 2021-09-13 | 改善肠道屏障功能母乳低聚糖组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113796546A true CN113796546A (zh) | 2021-12-17 |
Family
ID=78895146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111067369.0A Pending CN113796546A (zh) | 2021-09-13 | 2021-09-13 | 改善肠道屏障功能母乳低聚糖组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113796546A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644458A (zh) * | 2022-10-26 | 2023-01-31 | 君乐宝乳业集团有限公司 | 促进体格发育的营养组合物、其制备方法及其应用 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171166A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
US20120294840A1 (en) * | 2011-05-13 | 2012-11-22 | Glycosyn LLC. Trustees of Boston College | Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics |
WO2013025104A1 (en) * | 2011-08-16 | 2013-02-21 | Friesland Brands B.V. | Nutritional compositions comprising human milk oligosaccharides and uses thereof |
US20180220690A1 (en) * | 2015-08-04 | 2018-08-09 | Nestec S.A. | Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants |
CN109528777A (zh) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | 由鼠李糖乳杆菌和2`-岩藻糖基乳糖组成的组合物的应用 |
CN110839702A (zh) * | 2018-08-21 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | 一种改善婴幼儿肠道菌群丰度和粪便气味的母乳低聚糖组合物及其应用 |
CN110973263A (zh) * | 2019-12-19 | 2020-04-10 | 河北三元食品有限公司 | 一种含人乳低聚糖的婴幼儿营养组合物 |
CN111838683A (zh) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | 一种含有人乳低聚糖的益生元组合物及其应用 |
WO2020239724A1 (en) * | 2019-05-29 | 2020-12-03 | Frieslandcampina Nederland B.V. | Compositions comprising 2 -fucosyllactose and gos |
CN112075637A (zh) * | 2020-04-27 | 2020-12-15 | 合生元(广州)健康产品有限公司 | 一种减少肠道气体产生的组合物 |
CN112515170A (zh) * | 2019-11-29 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的乳双歧杆菌与益生元组合物及应用 |
CN112514997A (zh) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 改善肠道微环境健康的母乳低聚糖及其应用 |
WO2021078920A1 (en) * | 2019-10-24 | 2021-04-29 | Frieslandcampina Nederland B.V. | Compositions comprising 2'-fucosyllactose to prevent asthma |
CN112870233A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 包含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
CN112868800A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 含母乳低聚糖提高免疫力的婴幼儿配方奶粉及其制备方法 |
CN113194746A (zh) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | 用以改善胃肠屏障的包含人乳低聚糖的组合的营养组合物 |
-
2021
- 2021-09-13 CN CN202111067369.0A patent/CN113796546A/zh active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171166A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
US20120294840A1 (en) * | 2011-05-13 | 2012-11-22 | Glycosyn LLC. Trustees of Boston College | Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics |
WO2013025104A1 (en) * | 2011-08-16 | 2013-02-21 | Friesland Brands B.V. | Nutritional compositions comprising human milk oligosaccharides and uses thereof |
US20180220690A1 (en) * | 2015-08-04 | 2018-08-09 | Nestec S.A. | Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants |
CN110839702A (zh) * | 2018-08-21 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | 一种改善婴幼儿肠道菌群丰度和粪便气味的母乳低聚糖组合物及其应用 |
CN113194746A (zh) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | 用以改善胃肠屏障的包含人乳低聚糖的组合的营养组合物 |
CN109528777A (zh) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | 由鼠李糖乳杆菌和2`-岩藻糖基乳糖组成的组合物的应用 |
WO2020239724A1 (en) * | 2019-05-29 | 2020-12-03 | Frieslandcampina Nederland B.V. | Compositions comprising 2 -fucosyllactose and gos |
WO2021078920A1 (en) * | 2019-10-24 | 2021-04-29 | Frieslandcampina Nederland B.V. | Compositions comprising 2'-fucosyllactose to prevent asthma |
CN112515170A (zh) * | 2019-11-29 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的乳双歧杆菌与益生元组合物及应用 |
CN112870233A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 包含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
CN112868800A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 含母乳低聚糖提高免疫力的婴幼儿配方奶粉及其制备方法 |
CN110973263A (zh) * | 2019-12-19 | 2020-04-10 | 河北三元食品有限公司 | 一种含人乳低聚糖的婴幼儿营养组合物 |
CN112075637A (zh) * | 2020-04-27 | 2020-12-15 | 合生元(广州)健康产品有限公司 | 一种减少肠道气体产生的组合物 |
CN111838683A (zh) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | 一种含有人乳低聚糖的益生元组合物及其应用 |
CN112514997A (zh) * | 2020-11-30 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 改善肠道微环境健康的母乳低聚糖及其应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115644458A (zh) * | 2022-10-26 | 2023-01-31 | 君乐宝乳业集团有限公司 | 促进体格发育的营养组合物、其制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113796545B (zh) | 调节肠道免疫功能的母乳低聚糖组合物及其应用 | |
CN112514997B (zh) | 改善肠道微环境健康的母乳低聚糖及其应用 | |
CN110106119B (zh) | 一株分离自母乳的鼠李糖乳杆菌m9及其应用 | |
Ishibashi et al. | Bifidobacteria: their significance in human intestinal health | |
CN114854643B (zh) | 一种促进乳杆菌和双歧杆菌协同增殖的培养基及其应用 | |
CN111440750B (zh) | 一株具有缓解乳糖不耐受和降甘油三酯功能的动物双歧杆菌乳亚种及其应用 | |
CN111820419B (zh) | 靶向调控肠道艾克曼菌和短链脂肪酸产生菌的组合物 | |
CN111480849B (zh) | 母乳化的复合益生菌微胶囊粉及其制备方法和应用 | |
CN111213885A (zh) | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 | |
CN112869170A (zh) | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 | |
CN109497558A (zh) | 苦参药渣多糖合生元及其制备方法与应用 | |
Ai et al. | The specific use of alginate from Laminaria japonica by Bacteroides species determined its modulation of the Bacteroides community | |
CN116286551B (zh) | 长双歧杆菌婴儿亚种在调节体内脂肪代谢、塑形减脂改善肥胖方面的应用 | |
Ogata et al. | Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers | |
CN110627919B (zh) | 一种肠道益生元黑皮鸡枞菌多糖orp-1及其制备方法和用途 | |
CN105147715B (zh) | 一种蝙蝠蛾拟青霉中性胞外多糖的新用途 | |
CN113796546A (zh) | 改善肠道屏障功能母乳低聚糖组合物及其应用 | |
Niu et al. | Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice | |
CN111228316B (zh) | 用于改善糖尿病的复合益生菌 | |
CN112274577B (zh) | 包含芭蕉属物种发酵物的组合物的用途及益生质组合物 | |
CN105063128B (zh) | 一种调节肠道菌群的低分子量魔芋低聚糖的制备方法 | |
CN116769654A (zh) | 一株动物双歧杆菌乳亚种及其应用 | |
CN104780788A (zh) | 多糖用于护理的婴儿和/或婴儿的肠道健康的用途 | |
CN114574407B (zh) | 动物双歧杆菌乳亚种wkb99及其在制备改善代谢综合征制品方面的应用和产品 | |
CN116286535B (zh) | 一种含益生菌的胶原蛋白肽组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211217 |
|
RJ01 | Rejection of invention patent application after publication |